Sustained response to anlotinib in advanced pancreatic neuroendocrine carcinoma: A case report

Zhang,Yan; Wang,Yanchun; Wu,Jingjing; Zhong,Zhihong; Li,Jie; Chen,Xi

doi:10.3892/ol.2024.14271

Sustained response to anlotinib in advanced pancreatic neuroendocrine carcinoma: A case report

Authors:
- Yan Zhang
- Yanchun Wang
- Jingjing Wu
- Zhihong Zhong
- Jie Li
- Xi Chen
View Affiliations

Affiliations: Department of Oncology, The 900th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Fuzong Clinical College of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China, Department of Oncology, Fuzhou First Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian 350004, P.R. China, Department of Gastroenterology, People's Hospital of Fuan City, Ningde, Fujian 355000, P.R. China
Published online on: February 2, 2024 https://doi.org/10.3892/ol.2024.14271
Article Number: 138

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic neuroendocrine carcinoma (pNEC) is a type of pancreatic neuroendocrine neoplasm with a poor prognosis, and patients with metastatic pNEC have a survival time of only 8‑12 months. The treatment options for pNEC are minimal, and the prognosis is unfavorable. The present study reports the case of a 56‑year‑old male who was diagnosed with advanced pNEC with bone metastases in June 2018. The patient was treated with oral anlotinib after eight cycles of first‑line etoposide + cisplatin (EP) chemotherapy until July 2022. The adverse events that occurred during the treatment period were resolved with symptomatic management or drug dose reduction. At the time of writing this report, the patient's survival time was almost 60 months, which is rare for patients with pNEC. This case report suggests that patients with pNEC treated with first‑line EP regimen chemotherapy may have a sustained response to anlotinib.

View Figures

View References

1	Basu B, Sirohi B and Corrie P: Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer. 17:R75–R90. 2010. View Article : Google Scholar : PubMed/NCBI
2	Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA; WHO Classification of Tumours Editorial Board, : The 2019 WHO classification of tumours of the digestive system. Histopathology. 76:182–188. 2020. View Article : Google Scholar : PubMed/NCBI
3	Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T and Yao JC: Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Onco. l3:1335–1342. 2017. View Article : Google Scholar
4	Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, et al: Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. l40:313–318. 2010. View Article : Google Scholar : PubMed/NCBI
5	Mosalem O, Sonbol MB, Halfdanarson TR and Starr JS: Tyrosine kinase inhibitors and immunotherapy updates in neuroendocrine neoplasms. Best Pract Res Clin Endocrinol Metab. 37:1017962023. View Article : Google Scholar : PubMed/NCBI
6	Liao X and Zhang D: The 8th Edition American Joint Committee on cancer staging for hepato-pancreato-biliary cancer: A review and update. Arch Pathol Lab Med. 145:543–553. 2021. View Article : Google Scholar : PubMed/NCBI
7	Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ and Hou BH: Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol. 26:2305–2322. 2020. View Article : Google Scholar : PubMed/NCBI
8	Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, et al: Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: A randomised, double-blind, placebo-controlled phase 2 study. Br J Cancer. 125:366–371. 2021. View Article : Google Scholar : PubMed/NCBI
9	Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y and Lou L: Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 109:1207–1219. 2018. View Article : Google Scholar : PubMed/NCBI
10	Taurin S, Yang CH, Reyes M, Cho S, Coombs DM, Jarboe EA, Werner TL, Peterson CM and Janát-Amsbury MM: Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model. Int J Gynecol Cancer. 28:152–160. 2018. View Article : Google Scholar : PubMed/NCBI
11	Lin B, Song X, Yang D, Bai D, Yao Y and Lu N: Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 654:77–86. 2018. View Article : Google Scholar : PubMed/NCBI